Skip to main navigation Skip to search Skip to main content

Safety, Immunogenicity, and Efficacy of Quadrivalent HPV (Types 6,11,16,18) L1 Virus-Like Particle(VLP) Vaccine in Mid-Adult Women-The FUTURE III(Females Uninted to Unilaterally Reduce Endo/Ecto Cervical Cancer) Study

Stony Brook University

Project: Research

Project Details

StatusFinished
Effective start/end date07/23/04 → 04/29/11

Funding

  • Merck and Company: $20,527.20